Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2020 15:00 ET | Source: Celsion CORP

Celsion Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock

Lawrenceville, NJ, June 22, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to...
June 08, 2020 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
May 07, 2020 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces First Quarter 2020 Operating and Financial Results

Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation...
March 31, 2020 06:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update

QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse...
March 25, 2020 16:15 ET | Source: ProQR Therapeutics N.V.

ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
February 26, 2020 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update

Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal...
February 24, 2020 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Present at Cowen and Company 40th Annual Health Care Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
May 08, 2019 17:00 ET | Source: Celsion CORP

Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019

LAWRENCEVILLE, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
October 03, 2018 17:15 ET | Source: Celsion CORP

Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAWRENCEVILLE, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on September 28, 2018, the Compensation...
September 18, 2018 06:00 ET | Source: BCC Research

Gene Modification Therapy Market to See 49.9% Annual Growth Through 2023

WELLESLEY, Mass., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Recent advancements in genetic modification, including better delivery systems, more efficient and durable gene expression constructs, and...